Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 2, 2010, Pages 173-177

  Morsy, Mohamed A ^a   Ashour, Osama M ^a   Fouad, Amr A ^a   Abdel Gaber, Seham A ^a  

^a Minia University   (Egypt)

Author keywords

Gastric ulcer; Metformin; Rosiglitazone; Type 2 diabetes

Indexed keywords

CATALASE; MALONALDEHYDE; METFORMIN; NITRIC OXIDE; PROSTAGLANDIN E2; RANITIDINE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PYLORUS LIGATION; RAT; SINGLE DRUG DOSE; STOMACH JUICE; STOMACH PROTECTION; STOMACH ULCER; STREPTOZOCIN DIABETES;

ANIMALS; CATALASE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DINOPROSTONE; GASTRIC MUCOSA; HYPOGLYCEMIC AGENTS; INDOMETHACIN; MALE; MALONDIALDEHYDE; METFORMIN; MUCINS; NITRIC OXIDE; RATS; RATS, WISTAR; STOMACH ULCER; THIAZOLIDINEDIONES;

EID: 75649146989     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05250.x     Document Type: Article

References (48)

1. Boehme MW, Autschbach F, Ell C, Raeth U. Prevalence of silent gastric ulcer, erosions or severe acute gastritis in patients with Type 2 diabetes mellitus: A cross-sectional study. Hepatogastroenterology 2007 54 : 643 648.
2. Pietzsch M, Theuer S, Haase G, Plath F, Keyser M, Riethling AK. Results of systematic screening for serious gastrointestinal bleeding associated with NSAIDs in Rostock hospitals. Int. J. ClPharmacol. Ther. 2002 40 : 111 115.
3. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in Type 2 diabetes: A systematic review. Diabetologia 2006 49 : 434 441.
4. Isoda K, Young JL, Zirlik A et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 2006 26 : 611 617.
5. Correia S, Carvalho C, Santos MS et al. Metformin protects the brain against the oxidative imbalance promoted by Type 2 diabetes. Med. Chem. 2008 4 : 358 364.
6. Manning PJ, Sutherland WH, Walker RJ, Williams SM, de Jong SA, Berry EA. The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Diabetes Res. ClPract. 2008 81 : 209 215.
7. Morsy MA, Fouad AA. Mechanisms of gastroprotective effect of eugenol in indomethacin-induced ulcer in rats. Phytother. Res. 2008 22 : 1361 1366.
8. Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am. J. Gastroenterol. 2006 101 : 701 710.
9. Martin GR, Wallace JL. Gastrointestinal inflammation. A central component of mucosal defense and repair. Exp. Biol. Med. 2006 231 : 130 137.
10. Brzozowski T, Konturek PC, Pajdo R. et al. Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation: Focus on nitric oxide and lipoxins. J. Physiol. Pharmacol. 2008 59 : 89 102.
11. Masiello P, Broca C, Gross R. et al. Experimental NIDDM: Development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998 47 : 224 229.
12. Khattab MM, Gad MZ, Abdallah D. Protective role of nitric oxide in indomethacin-induced gastric ulceration by a mechanism independent of gastric acid secretion. Pharmacol. Res. 2001 43 : 463 467.
13. García-Bueno B, Caso JR, Pérez-Nievas BG, Lorenzo P, Leza JC. Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology 2007 32 : 1251 1260.
14. Verma S, Yao L, Dumont AS, McNeill JH. Metformin treatment corrects vascular insulin resistance in hypertension. J. Hypertens. 2000 18 : 1445 1450.
15. Prakash M, Balamurugan M, Parthasarathi K, Gunasekaran G, Cooper EL, Ranganathan LS. Anti-ulceral and anti-oxidative properties of 'earthworm paste' of Lampito mauritii (Kinberg) on Rattus norvegicus. Eur. Rev. Med. Pharmacol. Sci. 2007 11 : 9 15.
16. 5]enkephalinamide on gastric ulceration and transmucosal potential difference. Eur. J. Pharmacol. 1988 150 : 325 330.
17. Moore EW. Determination of pH by the glass electrode: pH meter calibration for gastric analysis. Gastroenterology 1968 54 : 501 507.
18. Sanyal AR, Denath OK, Bhattacharya SK, Gode KD. The effect of cyproheptadine on gastric acidity. In : Pfeiffer CJ (ed Peptic Ulcer. Scandinavian University Books, Munksgaard. 1971 312 318.
19. Winzler RJ. Determination of serum glycoproteins. Methods Biochem. Anal. 1955 2 : 279 311.
20. Feldman M. Gastric secretion. Normal and abnormal. In : Feldman M, Scharschmidt BF, Sleisenger MH (eds). Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management, 6th edn. WB Saunders, Philadelphia. 1998 587 603.
21. Hara N, Hara Y, Natsume Y, Goto Y. Gastric hyperacidity and mucosal damage caused by hypothermia correlate with increase in GABA concentrations of the rat braEur. J. Pharmacol. 1991 194 : 77 81.
22. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978 52 : 302 310.
23. Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao GS. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal. Biochem. 2002 306 : 79 82.
24. Sinha AK. Colorimetric assay of catalase. Anal. Biochem. 1972 47 : 389 394.
25. 2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-γ), reduce ischaemia/reperfusion injury of the gut. Br. J. Pharmacol. 2003 140 : 366 376.
26. Sener G, Sehirli AO, Gedik N, Dülger GA. Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs. Burns 2007 33 : 587 593.
27. Kavak S, Ayaz L, Emre M, Inal T, Tamer L, Günay I. The effects of rosiglitazone on oxidative stress and lipid profile in left ventricular muscles of diabetic rats. Cell Biochem. Funct. 2008 26 : 478 485.
28. Villegas I, Martín AR, Toma W, de la Lastra CA. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: Role of oxygen free radicals generation. Eur. J. Pharmacol. 2004 505 : 195 203.
29. Konturek PC, Brzozowski T, Kania J et al. Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/reperfusion in rat. Scand. J. Gastroenterol. 2003 38 : 468 476.
30. Slomiany BL, Slomiany A. Peroxisome proliferator-activated receptor gamma activation counters the detrimental effect of Helicobacter pylori lipopolysaccharide on gastric mucin synthesis. Inflammopharmacology 2003 11 : 223 236.
31. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 2004 286 : H742 8.
32. Brzozowski T, Konturek PC, Pajdo R. et al. Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): A new compound with potent gastroprotective and ulcer healing properties. Inflammopharmacology 2005 13 : 317 330.
33. Boyle JG, Logan PJ, Ewart MA et al. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J. Biol. Chem. 2008 283 : 11210 11217.
34. Pontsler AV, St Hilaire A, Marathe GK, Zimmerman GA, McIntyre TM. Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoproteJ. Biol. Chem. 2002 277 : 13029 13036.
35. 2 levels and smooth muscle relaxation in mouse isolated trachea. J. Pharmacol. Exp. Ther. 2005 314 : 995 1001.
36. García-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, Leza JC. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol. Psychiatry 2005 57 : 885 894.
37. Moulin D, Poleni PE, Kirchmeyer M et al. Effect of peroxisome proliferator activated receptor (PPAR) gamma agonists on prostaglandins cascade in joint cells. Biorheology 2006 43 : 561 575.
38. Tureyen K, Kapadia R, Bowen KK et al. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and Type-2 diabetic rodents. J. Neurochem. 2007 101 : 41 56.
39. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 2008 1244 : 164 172.
40. Liu DS, Liu WJ, Chen L et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats. Toxicology 2009 260 : 112 119.
41. Molloy AM, Ardill J, Tomkin GH. The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects. Diabetologia 1980 19 : 93 6.
42. Aleisa AM, Al-Rejaie SS, Bakheet SA et al. Effect of metformin on clastogenic and biochemical changes induced by adriamycin in Swiss albino mice. Mutat. Res. 2007 634 : 93 100.
43. Yamagishi S, Ueda S, Okuda S. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes. Med. Hypotheses 2007 69 : 922 924.
44. Calvert JW, Gundewar S, Jha S et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008 57 : 696 705.
45. Matsumoto T, Noguchi E, Ishida K, Kobayashi T, Yamada N, Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 2008 295 : H1165 76.
46. Marchetti P, Del Guerra S, Marselli L et al. Pancreatic islets from Type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformJ. ClEndocrinol. Metab. 2004 89 : 5535 5541.
47. Pari L, Saravanan R. Beneficial effect of succinic acid monoethyl ester on erythrocyte membrane bound enzymes and antioxidant status in streptozotocin-nicotinamide induced Type 2 diabetes. Chem. Biol. Interact. 2007 169 : 15 24.
48. Nath N, Khan M, Paintlia MK, Hoda MN, Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 2009 182 : 8005 8014.